On Monday, October 1, FDA’s Center for Biologics Evaluation and Research (CBER) issued a document outlining the policies and procedures for scheduling and conducting INitial Targeted Engagement for Regulatory Advice on CBER ProducTs (INTERACT) meetings. The document, entitled “SOPP 8214: INTERACT Meetings with Sponsors for Drugs and Biological Products,” applies to all products regulated by CBER and does not cover formal regulatory or device meetings.
INTERACT meetings are informal, non-binding consultative exchanges between sponsors and CBER representative during the early stages of product development which help sponsors address certain issues prior to a pre-IND meeting. The INTERACT program will replace the current pre- pre-investigational new drug (IND) meeting program for all biologic products.
The development of innovative investigational products can introduce a unique and unknown set of challenges. When this happens, it is helpful for sponsors to get FDA’s feedback and advice before they are ready for a pre-IND meeting. INTERACT meetings make this possible by providing sponsors with a mechanism for early communication with CBER.
INTERACT meetings allow sponsors to “obtain initial, non-binding advice from regarding chemistry, manufacturing and controls, pharmacology/toxicology, and/or clinical aspects of the development program,” by initiating targeted discussions focused on specific issues.
In the SOPP, FDA states that these informal meetings can:
INTERACT meetings are not intended to replace pre-IND meetings, nor are they an appropriate venue for FDA “to provide advice to sponsors who have yet to initiate any product development activities.”
INTERACT meetings are not required before a sponsor can request a pre-IND meeting. INTERACT meetings are held based on the availability of CBER resources; these meetings generally last for one hour and are held via teleconference only.
INTERACT meeting requests and packages must be submitted to CBER via email. “The cover letter and email subject line should be clearly marked as a request for an INTERACT meeting and identify the CBER Office where the request is directed.” Sponsors should consider the complexity of the questions being asked in the meeting request and limit the questions to those that can be reasonably answered in one hour.
Meeting packages are limited to no more than 50 pages and must include the following:
There are no formal performance goals set, however CBER attempts to schedule all INTERACT meetings within 21 days and conduct the meeting with 90 days of receiving the meeting request and package.
CBER may deny the request for an INTERACT meeting based on a substantive reason, but not simply due to the absence of a minor element of the meeting request or a minor element of the meeting package. If a meeting is denied, CBER will provide the sponsor with the reason for denial. FDA’s SOPPs include a number of reasons that a meeting request may be denied, which include:
CBER may also reschedule INTERACT meetings but must provide sponsors with a new date immediately upon rescheduling. If a sponsor wishes to cancel the meeting, they must provide CBER with written notification.
In the SOPP document, CBER details the procedures to be followed by CBER representatives when completing a number of tasks related to INTERACT meetings. In addition, FDA also outlines the responsibilities of CBER representatives regarding these meetings. For additional information on CBER’s responsibilities and procedures, view the full SOPP document.
Are you in the early stages of development for a CBER regulated product? Do you think you could benefit from an early INTERACT FDA meeting? We can help determine whether you qualify for an INTERACT meeting and, if you do, we can help you prepare and submit the meeting request and package and assist with the conduct of the actual meeting. To learn more about our services and how we can help you conduct a successful FDA meeting, contact us today.
April 18, 2016
On December 23, 2015, the FDA announced a proposed rule regarding the regulation of fixed-combination drugs. In its announcement, FDA proposed that its requirements for prescription...
December 14, 2018
On Tuesday, December 4th, FDA published the De Novo Classification Proposed Rule. If finalized, the rule would establish procedures for the De Novo classification process by facilitating appropriate...
October 22, 2018
On Friday, October 12th, FDA issued a guidance document entitled “Impact of Certain Provisions of the Revised Common Rule on FDA-Regulated Clinical Investigations.” The document aims to help...